Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement

PHASE3CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
OsteoarthritisPostoperative Pain
Interventions
DRUG

pregabalin

150 milligram (mg)/ day (double blind)

DRUG

pregabalin

300 mg/day (double blind)

DRUG

Placebo

Placebo

Trial Locations (27)

10021

Pfizer Investigational Site, New York

15232

Pfizer Investigational Site, Pittsburgh

18103

Pfizer Investigational Site, Allentown

19107

Pfizer Investigational Site, Philadelphia

19406

Pfizer Investigational Site, King of Prussia

21218

Pfizer Investigational Site, Baltimore

28207

Pfizer Investigational Site, Charlotte

32960

Pfizer Investigational Site, Vero Beach

35401

Pfizer Investigational Site, Tuscaloosa

35406

Pfizer Investigational Site, Tuscaloosa

35476

Pfizer Investigational Site, Northport

43214

Pfizer Investigational Site, Columbus

43215

Pfizer Investigational Site, Columbus

43220

Pfizer Investigational Site, Upper Arlington

60612

Pfizer Investigational Site, Chicago

61401

Pfizer Investigational Site, Galesburg

70503

Pfizer Investigational Site, Lafayette

70563

Pfizer Investigational Site, New Iberia

72205

Pfizer Investigational Site, Little Rock

75390

Pfizer Investigational Site, Dallas

77030

Pfizer Investigational Site, Houston

85023

Pfizer Investigational Site, Phoenix

331036

Pfizer Investigational Site, Miami

08234

Pfizer Investigational Site, Egg Harbor

08205

Pfizer Investigational Site, Pomona

08043

Pfizer Investigational Site, Voorhees Township

15213-2582

Pfizer Investigational Site, Pittsburgh

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00442546 - Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement | Biotech Hunter | Biotech Hunter